Comparison · NCT03910387-0f7283f1
Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) vs Group 2 (gemcitabine/nab-paclitaxel): Response Rate (RR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) vs Group 2 (gemcitabine/nab-paclitaxel): Response Rate (RR). Trial comparisons, record NCT03910387-0f7283f1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03910387-0f7283f1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.917 | 0.646 | 0.985 | wilson | |
| Risk in group 2 | 1 | 0.61 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0833 | -0.354 | 0.313 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.917 | 0.773 | 1.09 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) than on Group 2 (gemcitabine/nab-paclitaxel) | 12 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group 1 (gemcitabine/nab-paclitaxel and telotristat ethyl) | Patients receive gemcitabine/nab-paclitaxel combination chemotherapy on days 1, 8 and 15, and telotristat ethyl PO QD, BID, or TID on days 1 and 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Gemcitabine: Given gemcitabine/nab-paclitaxel combination therapy~Nab-paclitaxel: Given gemcitabine/nab-paclitaxel combination therapy~Telotristat Ethyl: Given PO | 11 | 12 | OG000 |
| Group 2 | Group 2 (gemcitabine/nab-paclitaxel) | Patients receive gemcitabine/nab-paclitaxel chemotherapy (at the discretion of the investigator) on days 1, 8 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Gemcitabine: Given gemcitabine/nab-paclitaxel combination therapy~Nab-paclitaxel: Given gemcitabine/nab-paclitaxel combination therapy | 6 | 6 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Response Rate (RR)
- Description
- Response rate (RR) will be assessed per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, in patients receiving telotristat ethyl (Group 1).
- Time frame
- Up to 2 years after study start
- Population
Source ClinicalTrials.gov
Trial
- Title
- Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
- NCT number
- NCT03910387
- Phases
- PHASE2
- Conditions
Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Gemcitabine, Nab-paclitaxel, Telotristat Ethyl
- Lead sponsor
- Emory University
- Results first posted
- 2025-12-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03910387?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03910387-0f7283f1